Spots Global Cancer Trial Database for azacytidine
Every month we try and update this database with for azacytidine cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma | NCT01983969 | Advanced Cancer... Lymphoma | Azacitidine Vorinostat Gemcitabine Busulfan Melphalan Dexamethasone Caphosol Glutamine Pyridoxine Rituximab | 15 Years - 65 Years | M.D. Anderson Cancer Center | |
| Azacytidine and Lymphocytes in Relapse of AML or MDS After Allogeneic Stem Cell Transplantation. | NCT02017457 | Acute Myelogeno... Myelodysplastic... | Donor lymphocyt... Azacytidine | 18 Years - | University Hospital of Mont-Godinne | |
| Evaluation of Cytidine Deaminase for Patient Suffering of a Myelodysplastic Syndrom or an AML Treated by Azacytidine | NCT02489929 | Myeloid Leukemi... Myelodysplastic... | blood samples azacytidine | 18 Years - 85 Years | Assistance Publique Hopitaux De Marseille | |
| Azacytidine + HAG Regimen vs. Azacytidine for Elderly Patients With Newly Diagnosed Myeloid Malignancy | NCT03873311 | Acute Myeloid L... | Azacytidine, HA... Azacytidine | 60 Years - 85 Years | Shenzhen Second People's Hospital | |
| Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML) | NCT02829840 | Leukemia FLT3-Mutated Ac... FLT3-Mutated Hi... | Ponatinib 5-azacytidine Phone Calls | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Venetoclax in Combination With Azacytidine in AML Patients Selected Using Ex Vivo Drug Sensitivity Screening | NCT04267081 | Acute Myeloid L... | Venetoclax | 18 Years - 100 Years | Helsinki University Central Hospital | |
| Study of Venetoclax in Combination With Azacytidine in AML Patients Selected Using Ex Vivo Drug Sensitivity Screening | NCT04267081 | Acute Myeloid L... | Venetoclax | 18 Years - 100 Years | Helsinki University Central Hospital | |
| Efficacy and Safety of ON 01910.Na in Myelodysplastic Syndrome (MDS) Patients With Trisomy 8 or Classified as Intermediate-1, -2 or High Risk | NCT00906334 | Myelodysplastic... | ON 01910.Na ON 01910.Na | 18 Years - | Traws Pharma, Inc. | |
| Bcl-2 Inhibitors Combined With Azacytidine and Chemotherapy in Elderly Patients With Previously Untreated AML | NCT05053425 | Acute Myeloid L... | Venetoclax Azacitidine Cladribine Cytarabine Idarubicin | 60 Years - | LanZhou University | |
| Azacytidine and Valproic Acid in Patients With Advanced Cancers | NCT00496444 | Advanced Cancer... | Azacitidine Valproic Acid | 2 Years - | M.D. Anderson Cancer Center | |
| Evaluation of Cytidine Deaminase for Patient Suffering of a Myelodysplastic Syndrom or an AML Treated by Azacytidine | NCT02489929 | Myeloid Leukemi... Myelodysplastic... | blood samples azacytidine | 18 Years - 85 Years | Assistance Publique Hopitaux De Marseille | |
| Azacytidine Plus Chidamide in the Treatment of Relapsed and Refractory Angioimmunoblastic T-cell Lymphoma | NCT05179213 | Angioimmunoblas... | Azacitidine Chidamide | 18 Years - | Peking Union Medical College Hospital | |
| Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma | NCT02701673 | Lymphoma | Busulfan Caphosol Glutamine Pyridoxine Belinostat Azacitidine Gemcitabine Melphalan Stem Cell Trans... | 15 Years - 65 Years | M.D. Anderson Cancer Center | |
| Study of Venetoclax in Combination With Azacytidine in AML Patients Selected Using Ex Vivo Drug Sensitivity Screening | NCT04267081 | Acute Myeloid L... | Venetoclax | 18 Years - 100 Years | Helsinki University Central Hospital | |
| Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS) | NCT02469415 | Leukemia | Pacritinib 5-azacitidine Decitabine | 18 Years - | M.D. Anderson Cancer Center | |
| Azacitidine in Treating Patients With Newly Diagnosed Previously Untreated or Secondary Acute Myeloid Leukemia Who Are Unsuitable For Intensive Chemotherapy | NCT00739388 | Leukemia | azacytidine | 18 Years - | Swiss Group for Clinical Cancer Research | |
| Phase I/II - Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML) | NCT02096042 | Leukemia | Brentuximab Ved... 5-Azacytidine | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Venetoclax in Combination With Azacytidine in AML Patients Selected Using Ex Vivo Drug Sensitivity Screening | NCT04267081 | Acute Myeloid L... | Venetoclax | 18 Years - 100 Years | Helsinki University Central Hospital | |
| Azacytidine and Valproic Acid in Patients With Advanced Cancers | NCT00496444 | Advanced Cancer... | Azacitidine Valproic Acid | 2 Years - | M.D. Anderson Cancer Center | |
| Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma | NCT02701673 | Lymphoma | Busulfan Caphosol Glutamine Pyridoxine Belinostat Azacitidine Gemcitabine Melphalan Stem Cell Trans... | 15 Years - 65 Years | M.D. Anderson Cancer Center | |
| Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation | NCT02196857 | Leukemia | Azacytidine Sorafenib | 18 Years - | M.D. Anderson Cancer Center | |
| Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS) | NCT02599649 | Leukemia | Lirilumab Nivolumab Azacitidine | 18 Years - | M.D. Anderson Cancer Center | |
| Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS) | NCT02599649 | Leukemia | Lirilumab Nivolumab Azacitidine | 18 Years - | M.D. Anderson Cancer Center | |
| Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies | NCT04648826 | Sarcomas Melanomas Germ Cell Tumor... Epithelial Mali... Pulmonary Metas... | AeroEclipse II ... Bintrafusp alfa Azacytidine | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma | NCT05355051 | Hodgkin's Lymph... | Azacytidine Pembrolizumab | 1 Year - | M.D. Anderson Cancer Center | |
| MA+AZA Regimen for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) | NCT06345365 | Acute Myeloid L... | mitoxantrone li... Daunorubicin,Ar... | 18 Years - 75 Years | Zhongnan Hospital | |
| Study of Azacytidine Followed by GM-CSF in Patients With Myelodysplastic Syndrome (MDS) | NCT01542684 | Leukemia | Azacytidine GM-CSF | 18 Years - | M.D. Anderson Cancer Center | |
| Evaluation of Cytidine Deaminase for Patient Suffering of a Myelodysplastic Syndrom or an AML Treated by Azacytidine | NCT02489929 | Myeloid Leukemi... Myelodysplastic... | blood samples azacytidine | 18 Years - 85 Years | Assistance Publique Hopitaux De Marseille | |
| Biological, Prospective Study Evaluating the Dosage of Plasma Cytokines Including the FLT3 Ligand and IL6 of Patients Treated With Non-intensive Chemotherapy | NCT06439199 | Acute Myeloid L... Myelodysplastic... Chronic Myelomo... | 18 Years - 99 Years | Nantes University Hospital | ||
| Azacytidine With Valproic Acid Versus Ara-C in Acute Myeloid Leukemia (AML)/ Myelodysplastic Syndrome (MDS) Patients | NCT00382590 | Acute Myelogeno... Myelodysplastic... Leukemia | 5-Azacytidine Ara-C Valproic Acid (... | 60 Years - | M.D. Anderson Cancer Center | |
| Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Lymphoblastic Leukemia Undergoing Allo-HSCT | NCT05809167 | Allogeneic Hema... Acute Lymphobla... | VEN+AZA+Modifie... | 8 Years - 65 Years | The First Affiliated Hospital of Soochow University | |
| Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML) | NCT02829840 | Leukemia FLT3-Mutated Ac... FLT3-Mutated Hi... | Ponatinib 5-azacytidine Phone Calls | 18 Years - | M.D. Anderson Cancer Center | |
| Azacytidine + HAG Regimen vs. Azacytidine for Elderly Patients With Newly Diagnosed Myeloid Malignancy | NCT03873311 | Acute Myeloid L... | Azacytidine, HA... Azacytidine | 60 Years - 85 Years | Shenzhen Second People's Hospital | |
| Azacytidine Plus Chidamide in the Treatment of Relapsed and Refractory Angioimmunoblastic T-cell Lymphoma | NCT05179213 | Angioimmunoblas... | Azacitidine Chidamide | 18 Years - | Peking Union Medical College Hospital | |
| A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML | NCT01861002 | Lymphoblastic L... Myelogenous Leu... | Azacytidine Fludarabine Cytarabine Intrathecal (IT... Intrathecal Met... | 1 Year - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| 5-Azacytidine (Azacytidine; Vidaza) in Chronic Lymphocytic Leukemia | NCT00413478 | Chronic Lymphoc... Leukemia | 5-Azacytidine | 18 Years - | M.D. Anderson Cancer Center | |
| 5-Azacitidine in Low-risk Myelodysplastic Syndromes (MDSs) | NCT00897130 | Myelodysplastic... | Azacytidine | 18 Years - | Università degli Studi di Brescia |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
